Infect Immun. 1993 September; 61(9): 3994–3997. | PMCID: PMC281106 |
Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels.
E Gotuzzo, B Butron, C Seas, M Penny, R Ruiz, G Losonsky, C F Lanata, S S Wasserman, E Salazar, J B Kaper
,
et al.Instituto de Medicina Tropical, Universidad Peruana Cayetano Heredia, Lima.
Abstract
Groups of 122 Peruvian adults of low socioeconomic level (SEL) and 125 of high SEL received a randomly allocated 5 x 10(9)- or 5 x 10(8)-CFU dose of CVD 103-HgR live oral cholera vaccine or a placebo. The vaccine was well tolerated. Vibriocidal seroconversions occurred in 78% of high-SEL and 72% of low-SEL subjects who ingested the high dose and in 78 and 49%, respectively, of those who received the low dose.
Full text
Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the
complete article (789K), or click on a page image below to browse page by page.
This article has been